Communicating Science to the Public: Context and Curiosity

https://www.niams.nih.gov/about/about-the-director/letter/communicating-science-public-context-and-curiosity

Dear Colleagues, We all share our research progress each day, whether through peer-reviewed journal articles, lectures, tweets, or dinner table chats. In our interactions, it is important that we use clear language to convey the exciting advances we are achieving in arthritis and musculoskeletal and skin diseases. Each of our varied audiences poses unique communication challenges, whether they be scientists and clinicians, students, policy makers, journalists, patients and caregivers or friends and family. Plain language is a powerful tool to explain our role in “turning discovery into health” – the NIH’s tagline – as we demonstrate transparency and accountability in

NIAMS’ Katz Receives Dermatologists’ Highest Honor

https://www.niams.nih.gov/newsroom/announcements/niams-katz-receives-dermatologists-highest-honor

NIAMS Director Dr. Stephen Katz was recently awarded the Gold Medal by the American Academy of Dermatologists (AAD). The Gold Medal is the Academy’s highest tribute, and is presented on a “very selective basis to acknowledge outstanding and exceptional service in the field of dermatology.” Katz has been director of the NIAMS since August 1995 and was also a senior investigator in the Dermatology Branch of the NCI from 1974 to 2014. He has focused his research on immunology and the skin. His work has demonstrated that skin is an important component of the immune system both in its normal

Honoring Health — Addressing the Opioid Overdose Crisis and Other Drug Use in Your Community — March 2018

https://www.niams.nih.gov/newsletters/aian-newsletter/2018/aian-newsletter-march-2018

*/ /*--> */ /*--> */ /*--> */ Addressing the Opioid Overdose Crisis and Other Drug Use in Your Community Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl and pain relievers available legally by prescription, such as oxycodone (OxyContin ® ), hydrocodone (Vicodin ® ), codeine, morphine and many others. Prescription pain relievers have been used for years to treat chronic pain, cough and diarrhea. Opioid pain relievers are generally safe when taken for a short time and as prescribed by a doctor, but can be dangerous when misused. Regular use—even as

Optimizing Steroid Treatment for Duchenne Muscular Dystrophy

https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-treatment-duchenne-muscular-dystrophy

Summary Research funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has revealed insights into glucocorticoid steroid treatment for Duchenne muscular dystrophy (DMD). Scientists determined mechanisms of how glucocorticoid steroids improve muscle repair and function in mouse models of acute muscle injury and muscular dystrophy, according to a study in The Journal of Clinical Investigation . In a second paper in The Lancet , an international team found that in patients with DMD, long-term glucocorticoid steroid treatment delayed loss of muscle strength and function and decreased risk of death. Background DMD is a

The Role of the Microbiota in Eczema: Findings Suggest That Striking the Right Balance Keeps the Disease at Bay

https://www.niams.nih.gov/newsroom/spotlight-on-research/role-microbiota-eczema-findings-suggest-striking-right-balance-keeps

*/ Research suggests that the bacterium, Staphylococcus aureus , plays a role in the skin condition, atopic dermatitis. Credit: Heidi H. Kong, M.D., M.H.Sc., National Institute of Arthritis and Musculoskeletal and Skin Diseases. Microbes living on the skin are coming under increasing scrutiny as the cause of the most common type of eczema, called atopic dermatitis. A new pair of studies focus specifically on the bacterium Staphylococcus aureus as playing a role in driving the disorder. The studies – one from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the other from the University of

NIH program to accelerate therapies for arthritis, lupus releases first datasets

https://www.niams.nih.gov/newsroom/press-releases/nih-program-accelerate-therapies-arthritis-lupus-releases-first-datasets

Datasets characterizing individual cells in rheumatoid arthritis and systemic lupus erythematosus disease tissue from the Accelerating Medicines Partnership for Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Phase I study are now available to the research community. Scientists from across the biomedical research community can access the AMP RA/SLE datasets to explore important research questions about these autoimmune conditions. “This pioneering program seeks to speed the development of new ways to combat a range of devastating diseases that affect millions of people,” said National Institutes of Health Director Francis S. Collins, M.D, Ph.D. “AMP RA/SLE is entering an exciting phase

NIAMS Update — February 22, 2018

https://www.niams.nih.gov/newsletters/niams-update/2018/niams-update-february-22-2018

*/ /*--> */ /*--> */ /*--> */ SPOTLIGHT Letter From Dr. Stephen I. Katz: From Basic Science to Clinical Breakthroughs—the NIAMS Intramural Research Program Dear Colleagues, The first NIAMS Advisory Council meeting of the year gives the Institute an opportunity to share progress with members about the activities of the NIAMS Intramural Research Program (IRP). The annual presentations from NIAMS Scientific Director John J. O’Shea, M.D., and Clinical Director Richard Siegel, M.D., Ph.D., are a special highlight for me. These talks illustrate how the IRP exemplifies the best qualities of the National Institutes of Health (NIH) Intramural Research Program —

NIAMS Awards Five Centers of Research Translation

https://www.niams.nih.gov/newsroom/announcements/niams-awards-five-centers-research-translation

Continuing its commitment to support translational research, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health announces five Centers of Research Translation (CORT) (P50) awards. CORTs foster the application of basic research to human diseases within the NIAMS mission. Synergistic teams of scientists carry out these programs to address significant translational research challenges. Each CORT contains a minimum of three highly meritorious research components: one or more translational research projects, one or more research cores, and an administrative core. Through the CORTs, investigators identify new therapeutic targets, develop treatments or diagnostics, or
Subscribe to